Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 EZH2: an epigenetic gatekeeper promoting lymphomagenesis.

Literature DB >> 23680141

EZH2: an epigenetic gatekeeper promoting lymphomagenesis.

Abstract

In this issue of Cancer Cell, Béguelin and colleagues highlight EZH2 as an essential regulator for B cell activation and report an addiction of germinal center-derived neoplasms to EZH2 activity. This reversible process is specifically targetable and hence presents high translational value for lymphoma therapy.

Entities: Disease Species

Mesh：

Substances：

Year: 2013 PMID： 23680141 DOI： 10.1016/j.ccr.2013.04.028

Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743

Keyword Cloud
Cited

11 in total

1. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.

Authors: Pradeep Kumar Kopparapu; Sujata Bhoi; Larry Mansouri; Laleh S Arabanian; Karla Plevova; Sarka Pospisilova; Agata M Wasik; Giorgio Alberto Croci; Birgitta Sander; Marco Paulli; Richard Rosenquist; Meena Kanduri
Journal: Epigenetics Date: 2016-04-06 Impact factor: 4.528

Review 2. New drugs for new targets in lymphoma.

Authors: Anas Younes
Journal: Hematol Oncol Date: 2019-06 Impact factor: 5.271

Review 3. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.

Authors: Aristeidis Chaidos; Valentina Caputo; Anastasios Karadimitris
Journal: Ther Adv Hematol Date: 2015-06

Review 4. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors: Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal: Mod Pathol Date: 2016-08-01 Impact factor: 7.842

5. Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.

Authors: Biao Lu; Xiaodong Shen; Lei Zhang; Dong Liu; Caihua Zhang; Jingsong Cao; Ru Shen; Jiayin Zhang; Dan Wang; Hong Wan; Zhibin Xu; Ming-Hsun Ho; Minsheng Zhang; Lianshan Zhang; Feng He; Weikang Tao
Journal: ACS Med Chem Lett Date: 2018-01-29 Impact factor: 4.345

6. Long noncoding RNA-LET, which is repressed by EZH2, inhibits cell proliferation and induces apoptosis of nasopharyngeal carcinoma cell.

Authors: Qiuzhen Sun; Hongbing Liu; Lihua Li; Shaorong Zhang; Ke Liu; Yuehui Liu; Chunping Yang
Journal: Med Oncol Date: 2015-08-05 Impact factor: 3.064

EZH2: an epigenetic gatekeeper promoting lymphomagenesis.

1. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.

Review 2. New drugs for new targets in lymphoma.

Review 3. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.

Review 4. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

5. Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.

6. Long noncoding RNA-LET, which is repressed by EZH2, inhibits cell proliferation and induces apoptosis of nasopharyngeal carcinoma cell.

7. A DNA methylation map of human cancer at single base-pair resolution.

8. 5-Hydroxyindole-Based EZH2 Inhibitors Assembled via TCCA-Catalyzed Condensation and Nenitzescu Reactions.

9. Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma.

10. Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features.